Navigation Links
NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
Date:8/21/2008

SAN DIEGO, Aug. 21 /PRNewswire/ -- NovaRx Corporation announced today that the company initiated its pivotal Phase III clinical trial of Lucanix(R) (belagenpumatucel-L) in the treatment of advanced non-small cell lung cancer (NSCLC). The first patient enrolled in the study was treated by Dr. Lyudmila Bazhenova the trial's principal investigator at the University of California, San Diego School of Medicine.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080821/LATH009-a)

(Photo: http://www.newscom.com/cgi-bin/prnh/20080821/LATH009-b)

The study is designated as the STOP trial because of its expected endpoints: Survival; Tumor-free, Overall; and Progression-free. It is an international, multicenter, randomized, double-blind study involving up to 700 individuals with advanced stage NSCLC, and will be conducted at approximately 90 clinical sites in the U.S., Canada, India, and Europe.

In a Phase II clinical trial, two-year survival among patients with stages IIIB and IV disease who received Lucanix(R) was significantly longer than that of individuals being treated with the current standard of care. A second, investigator-initiated phase II study supported these results.

In contrast to conventional cancer therapies, where systemic chemotherapeutic drugs nonspecifically kill normal cells as well as tumor cells, the therapeutic vaccine developed by NovaRx induces the patient's immune system to specifically target the cancer. In phase II clinical studies to date, the side effects of this treatment have included redness or soreness at the injection site.

"In medical research, you see something like this once in a lifetime," said John Nemunaitis, M.D., executive director at the Mary Crowley Medical Research Center in Dallas, TX and principal investigator of both the
'/>"/>

SOURCE NovaRx Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. NeoStem Expands Adult Stem Cell Collection Network, Gains Footprint in Key Los Angeles Market and Initiates Waitlist
5. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
6. Vista Partners Initiates Coverage on MediciNova Inc. (Nasdaq: MNOV)
7. Oncothyreon initiates Phase 1 trial of PX-866 cancer compound
8. Scimitar Equity, LLC Initiates Coverage Review of VioQuest Pharmaceuticals, Inc.
9. Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer
10. Genmab Initiates Zalutumumab Combination Study in Colorectal Cancer
11. Vista Partners Initiates Coverage on Synvista Therapeutics, Inc. (AMEX: SYI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
(Date:8/29/2014)... August 29, 2014 Intrinsic Imaging, ... certified, GAMP® 5 compliant imaging core lab, announced ... Phase II clinical trial to assess a new ... this trial, Intrinsic Imaging will provide comprehensive imaging ... protocol and charter development, site qualification, site training ...
(Date:8/28/2014)... Lawrence, MA (PRWEB) August 28, 2014 “This ... single test to screen from 0 to 150 ppb,” said ... test is a significant benefit to plant owners and USDA-GIPSA ... corn and other commodities. Testing can take place in a ... Not only can the plant test the feed and grain ...
(Date:8/28/2014)... The ability for organizations to attract top ... individuals to perform at the highest of levels, are ... to compete in this post–recession era. The pharmaceutical ... the sector increasingly focuses on the importance of employee-fit ... real results on the organization's development and the innovation ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... for ... Injured Service Members, CLEVELAND, April 17 Cleveland Clinic ... to develop,innovative medical therapies for the treatment of wounded service ... total of $42.5,million awarded over 5 years to create a ...
... YORK, April 17 The market for congestive ... billion in 2007, and is,expected to reach $30 ... by,Kalorama Information, Congestive Heart Failure: Major World Markets, ... three factors: an,increased incidence of CHF, the application ...
... April 17 Spherix Incorporated,(Nasdaq: SPEX ) announced ... Mr. Brown will be monitoring and overseeing all aspects ... of Naturlose(R) as a,treatment for Type 2 diabetes. The ... agreement with the Contract Research Organization (CRO),take over full ...
Cached Biology Technology:Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded 2Cleveland Clinic and Rutgers to Lead Newly Formed Institute for War Wounded 3Genomics Likely to Replace Traditional Drug Therapies in Treating CHF 2Spherix Hires Key Employees 2
(Date:8/28/2014)... (ESA) is pleased to announce the selection of Dr. ... Honorary Membership acknowledges those who have served ESA for ... affairs of the Society that has reached an extraordinary ... ESA Governing Board and then voted on by the ... Awards Ceremony at Entomology 2014, ESA,s Annual Meeting in ...
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
(Date:8/28/2014)... are healthier for your neighbors than traditional cigarettes, ... to a new study from USC. , Scientists ... 10-fold decrease in exposure to harmful particles, with ... exposure to some harmful metals in second-hand e-cigarette ... While tobacco smoke contains high levels of polycyclic ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2Second-hand e-cig smoke compared to regular cigarette smoke 2
... used to track the source of illegal drugs, explosives, ... new uses: detecting rapidly growing cancers and studying obesity ... isotope ratio mass spectrometry," can determine where a substance ... an element in the substance ?such as the ratio ...
... to fewer "superbugs." That's the take-home message behind ... of Clinical Infectious Diseases, now available online. The ... respiratory tract infections resulted in lower rates of ... commonly called "superbugs," are fast becoming a problem ...
... year, researchers at the University of Pennsylvania School of ... and an Epstein-Barr Virus (EBV) protein known to be ... demonstrated a new mechanism by which EBV can transform ... cells, which can lead to B-cell lymphomas. Now, they ...
Cached Biology News:War on terror meets war on cancer 2War on terror meets war on cancer 3War on terror meets war on cancer 4War on terror meets war on cancer 5War on terror meets war on cancer 6Reducing antibiotic use lowers rates of drug-resistant bacteria 2Mechanism for Epstein-Barr virus protein's role in blood cancers discovered 2
... strain ideally suited as an initial cloning ... blue/white screening capability (with appropriate plasmids) and ... yields of excellent quality plasmid DNA. The ... as a stringent host due to the ...
... an Affinity Chitin-binding Tag) utilizes the inducible ... (termed inteins) to purify recombinant proteins by ... and 2). This system distinguishes itself from ... to separate a recombinant protein from the ...
... imaging system from Molecular Devices is ... for automated acquisition and analysis of ... ImageXpressULTRA is powered by MetaXpress, ... acquisition, image storage and analysis. MetaXpress ...
... Cell Transformation Detection Assay is an anchorage-independent ... considered the most stringent assay for detecting ... assay, cells (pre-treated with carcinogens or carcinogen ... soft agar medium for 21-28 days. ...
Biology Products: